Recent News

• 11.13.2025 - BESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus
• 11.13.2025 - Transplant and Trials: Redefining Care
• 09.24.2025 - Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
• 09.18.2025 - Extending the life of transplanted kidneys
• 09.05.2025 - Xenotransplantation Moving Closer to Becoming a Clinical Reality
• 09.05.2025 - Cantor Global Healthcare Conference
• 08.14.2025 - Xenotransplantation at the brink of breakthrough: A new era in organ transplantation
• 08.14.2025 - Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
• 08.12.2025 - Eledon Pharmaceuticals’ ‘encouraging’ kidney transplant results
• 08.06.2025 - Eledon Pharmaceuticals Updated Phase 1b Tegoprubart Data at WTC 2025

Recent Filings

• 11.13.2025 - 8-K Current report
• 11.13.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.07.2025 - EX-99.1 EX-99.1
• 11.07.2025 - 8-K Current report
• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]